A Retrospective Analysis of Reporting of Adverse Drug Reactions in a Tertiary Care Teaching Hospital: One Year Survey. 2016

Anuj Kumar Pathak, and Manish Kumar, and Shambhu Dokania, and Lalit Mohan, and Harihar Dikshit
Senior Resident, Department of Pharmacology, IGIMS , Sheikhpura, Patna, Bihar, India .

BACKGROUND Pharmacovigilance (PV) is related to detection, assessment, understanding and prevention of Adverse Drug Reactions (ADRs) which are incurred when drug is made available in the market and used in different physiological conditions. In many countries, ADRs ranks among the top ten leading cause of morbidity and mortality. There is a lack of formal culture for monitoring and reporting of ADRs in India, with ADR reporting rate being only 1% as compared to 5% in world. This type of academic detailing activity helps to create awareness of ADR reporting in the institutions. OBJECTIVE This study was planned to evaluate and analyse the incidence and patterns of ADRs in various inpatient and outpatient departments of hospital. METHODS This was an observational, retrospective and record based study conducted by analysing the spontaneous ADR forms, collected over a period of 12 months (September 2014 to August 2015) at Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India. RESULTS During the period of one year, 292 ADR forms were collected from 4,34,965 patients attending OPD and inpatients of the hospital. Incidence of ADR was 0.67 per thousand patients and average of around 24 ADR collected per month. Male:Female ratio was 1.30. Adolescent (16-30 yr) was the most common age group affected. Department of Skin and VD reported the maximum number of ADRs (33.22%), followed by the Departments of Oncology (18.84%). Antibiotics were the most common drug implicated followed by anticancer drugs. CONCLUSIONS ADR reporting is an ongoing and continuous process. Studies from the institute helps to identify and rectify the problems related to ADR reporting. Pitfalls can be addressed by creating awareness among physicians and the patients to achieve finally the goal of Pharmacovigilant India.

UI MeSH Term Description Entries

Related Publications

Anuj Kumar Pathak, and Manish Kumar, and Shambhu Dokania, and Lalit Mohan, and Harihar Dikshit
October 2018, Turkish thoracic journal,
Anuj Kumar Pathak, and Manish Kumar, and Shambhu Dokania, and Lalit Mohan, and Harihar Dikshit
January 2016, Perspectives in clinical research,
Anuj Kumar Pathak, and Manish Kumar, and Shambhu Dokania, and Lalit Mohan, and Harihar Dikshit
March 2024, Cureus,
Anuj Kumar Pathak, and Manish Kumar, and Shambhu Dokania, and Lalit Mohan, and Harihar Dikshit
September 2006, Pharmacological research,
Anuj Kumar Pathak, and Manish Kumar, and Shambhu Dokania, and Lalit Mohan, and Harihar Dikshit
November 2022, Journal of family medicine and primary care,
Anuj Kumar Pathak, and Manish Kumar, and Shambhu Dokania, and Lalit Mohan, and Harihar Dikshit
April 2012, Journal of clinical pharmacology,
Anuj Kumar Pathak, and Manish Kumar, and Shambhu Dokania, and Lalit Mohan, and Harihar Dikshit
August 2008, Pharmacoepidemiology and drug safety,
Anuj Kumar Pathak, and Manish Kumar, and Shambhu Dokania, and Lalit Mohan, and Harihar Dikshit
February 2017, Therapeutic advances in drug safety,
Anuj Kumar Pathak, and Manish Kumar, and Shambhu Dokania, and Lalit Mohan, and Harihar Dikshit
January 2017, Perspectives in clinical research,
Anuj Kumar Pathak, and Manish Kumar, and Shambhu Dokania, and Lalit Mohan, and Harihar Dikshit
May 2004, Indian journal of medical sciences,
Copied contents to your clipboard!